Q-omics provides the consensus-scored MEIKIN profile across patient tissues and cancer cell-line models. MEIKIN expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, MEIKIN is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, MEIKIN RNA expression shows 7,075 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight DLBC, BRCA, and BLCA as cancer lineages where MEIKIN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEIKIN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEIKIN survival associations across molecular data types. MEIKIN RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEIKIN RNA expression–survival associations across cancer types. High MEIKIN expression shows unfavorable associations in DLBC, BLCA, READ, UCS, ESCA and LGG. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for MEIKIN RNA expression.
This table summarizes MEIKIN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MEIKIN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEIKIN shows higher tumor expression in BRCA, LUAD, COAD, STAD, KIRC and KIRP. The BRCA box plot shows higher MEIKIN RNA expression in tumor versus normal tissue (log2 FC = +0.087, t-test p < 0.001).
This table shows molecular features associated with MEIKIN in patient tissues and cancer cell lines. In patient samples, MEIKIN shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MEIKIN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
